Saturday 17 October 2026
Export OGEN’s income statement to Excel — free account
Oragenics, Inc.
OGEN Healthcare Biotechnology
Oragenics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $37,700.00, down 71.3% from fiscal 2022. In the quarter to June 2026, EPS grew 81.6% and free cash flow fell 66.4%, each against the same quarter a year earlier.
0.43
0.01
−2.27%
Follow OGEN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(192.73%) | (243.94%) | (311.00%) | (1,307.07%) | |
| (121.77%) | (170.58%) | (173.03%) | (264.23%) | ||
ROIC |
0.00% | 0.00% | (8,025.60%) | 0.00% | |
Return on Tangible Assets |
(110.92%) | (118.85%) | (158.96%) | (274.71%) | |
Average Days of Receivables |
— | 0.00 | — | — | |
Free Cash Flow per Share |
(5.40) | (4.29) | (2.17) | (2.30) | |
Free Cash Flow |
(8.43) | (9.25) | (9.33) | (10.21) | |
| Other line items | |||||
Cash ROIC |
(39.70%) | (55.43%) | (75.96%) | (135.47%) | |
Accounts Receivable Turnover |
— | 0.00 | — | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(12.95) | (11.91) | (16.24) | (562.93) | |
Operating CF/Net income |
0.77 | 0.94 | 0.95 | 1.01 | |
Depreciation/Fixed assets |
0.00 | 0.00 | — | — | |
Capex/Depreciation |
0.00 | 0.00 | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(5.40) | (4.29) | (2.17) | (2.30) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates